Document is current
Any future updates will be listed below
-
Authors
Dominguez-Pinilla, Nerea
González-Granado, Luis Ignacio
Gonzaga, Aitor
López Diaz, María
Castellano Yáñez, Cecilia
Aymerich, Clara
Freire, Xabier
Ordoñez, Olga
Diaz de Atauri, Álvaro Gimeno
Albi Rodríguez, María Salomé
Martínez López, Elisa
Iñiguez, Rodrigo
Serrano Garrote, Olga
Frontiñán, Almudena Castro
Andreu, Etelvina
Gutierrez-Vilchez, Ana María
Anton-Bonete, Marga
Martinez-Navarrete, Gema
Castillo-Flores, Nerea
Prat-Vidal, Cristina
Blanco, Margarita
Morante Valverde, Rocío
Fernandez, Eduardo
Querol, Sergi
Hernández-Blasco, Luis Manuel
Belda-Hofheinz, Sylvia
Soria, Bernat
-
Funding
Funding for this research was provided by:
Al-Andalus Biopharma SL (Al-Andalus Biopharma SL)
Agencia Valenciana de Innovación (AVI-GVA COVID-19-068, GVA-COVID19/2021/047)
Juvenile Diabetes Research Foundation (JDRF 2-SRA-2019-837)
Instituto de Salud Carlos III (ICI21/00016, DTS19/00175)
Université Toulouse III - Paul Sabatier (FIS PI21/01642)
Institute of Health Carlos III (PDC2022-133952-100)
- License Information
-
More Information
Article History
Received: 29 January 2025
Accepted: 19 March 2025
First Online: 5 April 2025
Declarations
:
: University Hospital 12 de Octubre (Madrid, Spain) Ethical Committee and AEMPS Permission number SLC59890178876, to the project entitled “Consecutive IntraBronchial Administration of Wharton’s Jelly-Derived Mesenchymal Stromal Cells in ECMO-Supported Pediatric Patients with End-Stage Interstitial Lung Disease: A Safety and Feasibility Study (CIBA Method)”.
: Informed consent was obtained from all subjects involved in the study.
: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
: The study was conducted in accordance with the Declaration of Helsinki, and following advice from the European Medicines Agency (EMA) on Advanced Therapy Medicinal Products (ATMP), we obtained informed consent from the patient’s family, and Compassionate Use permission from the Spanish Agency of Medicines and Medical Devices (AEMPS) (Permission number SLC59890178876, August 16, 2023).
